Medical treatment of viral pneumonia including SARS in immunocompetent adult

VCC Cheng¹, BSF Tang¹, AKL Wu¹, CM Chu², KY Yuen¹

Centre of Infection, Queen Mary Hospital, The University of Hong Kong¹; Department of Medicine, United Christian Hospital²; Hong Kong Special Administrative Region, China

Correspondence to: Professor K Y Yuen, Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China (E mail: kyyuen@hkucc.hku.hk)

Keywords: Viral pneumonia; Treatment; SARS; Immunocompetent host
Abstract

Since no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella-zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs 42.1%) and hantavirus (13.3% vs 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella-zoster virus may be associated with a lower mortality than acyclovir alone (0% vs 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs 2.3% vs 7.7% respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid.
**Introduction**

The start of the new millennium is marked by two emerging infectious diseases coming from wild game food animals and poultry [1, 2]. Both SARS coronavirus (SARS-CoV) and avian influenza A H5N1 virus predominantly manifest as acute community acquired pneumonia with no response to empirical treatment by antibacterials covering typical and atypical agents [3-7]. SARS-CoV and avian influenza A H5N1 pneumonia are associated with significant mortality [7, 9]. Unfortunately, few prospective studies have been performed with documentation of the virus load changes during the course of illness for any respiratory viral pneumonia [8, 10]. The literature on the histological changes or pathogenesis of this condition is scarce. No randomized placebo-controlled treatment trial has ever been conducted. Such lack of data was often attributed to the lack of rapid diagnostic tests and effective antivirals. During the SARS outbreak, the empirical use of ribavirin and steroids were regarded as controversial [11-14]. Due to the explosive nature of the outbreak, randomized controlled trials on treatment could not be organized. Therefore, we attempt to review the literature on the rationale and strategy used in the treatment of acute community acquired viral pneumonia in immunocompetent adults. Virus load data and serological changes of acute respiratory viral pneumonia available in the literature, as well as from our SARS patients were included in this analysis.
**Materials and methods**

All the case reports and series with clinical details involving medical therapy of viral pneumonia including SARS in patients aged 15 years or above were included in this review. Patients with immunosuppressive conditions such as congenital or acquired immunodeficiencies, solid or marrow transplants, undergoing chemotherapy, and pregnancy were excluded. Where appropriate, the cited bibliographies were also retrieved for analysis.

Preliminary review of these publications suggested that viral pneumonia caused by SARS-CoV constituted the majority of cases reported in the literature. However, similar to other causes of viral pneumonia, little information on the virus load changes with respect to treatment was systematically reported. Therefore laboratory data from our cohort of 152 SARS patients who fulfilled the modified WHO definition were retrieved [5]. Virus load was measured on nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset. Part of these data was previously reported [8, 10, 15, 16]. The virus load results were correlated with the specific antiviral regimens, namely ribavirin with and without lopinavir/ritonavir for SARS. Serial quantitative RT-PCRs and IgG titers of SARS-CoV were performed in 12 randomly selected patients who were treated with ribavirin and corticosteroid on day 5, 10, 15 and 20 after onset of symptoms. To compare the serial virus load and antibody seroconversion with other respiratory virus infections, the English-language literature was searched to identify studies with detailed description of serial virus load and antibody titers during the course of infection.
Results

In the literature review, there were 1997 and 322 English publications on human studies identified in PubMed when the combination of keywords “virus, pneumonia, treatment” and “SARS, treatment” were used on 11 January 2004 respectively. Among the 1997 publications, those related to HIV and AIDS patients (950), cancer and transplant patients (501), and vaccine and immunization topics (287), were excluded. The remaining 259 papers were retrieved and analyzed. All the 322 SARS paper were retrieved and analyzed. Subsequent PubMed search using the keywords of “influenza, pneumonia, treatment”, “respiratory syncytial virus, pneumonia, treatment”, “varicella, pneumonia, treatment”, “adenovirus, pneumonia, treatment”, and “hantavirus pulmonary syndrome, treatment” identified another 623, 267, 240, 146, and 83 papers respectively. The cited bibliographies, if relevant, were also included in this review. However, only 62 of these 1940 papers contained clinical details and information on the medical treatment of viral pneumonia (44 papers) and SARS (18 papers) respectively.

Of the 302 patients with non-SARS viral pneumonia in 44 case reports or series (table 1), their etiological diagnoses of human influenza A (n=38), avian influenza A H5N1 (n=12), varicella-zoster virus (VZV) (n=120), adenovirus (n=29), hantavirus (n=100), respiratory syncytial virus (RSV) (n=1), measles (n=1), and Epstein-Barr virus (EBV) (n=1), were documented by a combination of clinical features, radiographic changes, virological and serological tests [6, 7, 17-58]. Demographic details were mentioned in 171 (56.6%) patients. There were 113 males and 58 females, with a median age of 31 years (ranged 15-88). The small number of patients suffering from pneumonia caused by RSV, measles,
EBV precluded any meaningful analysis or discussion [56-58]. As for the other agents, the overall mortality ranges from 9.2% (VZV), 20.7% (adenovirus), 31.6% (human influenza A), 49% (hantavirus) to 66.7% (avian influenza A H5N1).

In the treatment of human influenza A infection, antiviral agents such as rimantadine (1 patient), oseltamivir (5 patients), and a combination of rimantadine and oseltamivir had been used at a median of 3 days (ranged 1-7 days) after admission [20-23]. High dose corticosteroid without antiviral therapy was also attempted [20-22]. The dose of steroids ranged from hydrocortisone 250 mg ivi every 4 hours to methylprednisolone 500 mg ivi every 6 hours [21, 22]. Amantadine (4 patients), oseltamivir (3 patients), and a combination of antivirals and corticosteroid (3 patients) had also been used in the treatment of avian influenza A H5N1 [6, 7]. There was no apparent benefit since the antiviral agents were started at a median of 5 days (ranged 0-5 days) after admission. Corticosteroid such as intravenous methylprednisolone 1-2 mg/kg every 6 hourly for 3 to 4 days had been given in 3 mechanically ventilated patients but 2 of them died of acute respiratory distress syndrome [6, 7].

As for VZV pneumonia, antiviral therapy including intravenous acyclovir 10-15 mg/kg every 8 hourly for 7 to 10 days was initiated in 66 out of 120 patients [26-38]. Two patients were treated with vidarabine before the widespread use of acyclovir [27, 38]. Corticosteroids were combined with acyclovir in 17 patients [28, 29, 39-41]. The dosage and duration of steroids were quite variable (table 1) [29, 39-41]. Two patients received intravenous immunoglobulin (IVIG) together with intravenous acyclovir had a favorable
outcome [42, 43]. The mortality of patients who received acyclovir or vidarabine alone was 7 out of 68 (10.3%), whereas 4 patients managed with supportive care died. Only 1 out of 25 patients died if intravenous acyclovir was initiated within 4 days of admission [27, 34, 35]. There was no death in patients treated with a combination of acyclovir and immunomodulators such as corticosteroid and IVIG [28, 29, 39-43].

As for adenoviral pneumonia, no antiviral was ever used for their treatment. Two of 4 (50%) patient receiving steroid died, which appeared to be higher than patients managed conservatively [21, 44-50]. The mortality for hantavirus pulmonary syndrome treated with intravenous ribavirin (47.7%) appeared to be only slightly lower than those treated conservatively (63.4%) [51-55]. The use of methylprednisolone was associated with a dramatic decrease of mortality to 13.3% [52, 53].

Though there were 849 cases of SARS with treatment details reported in the literature, many of these patients were diagnosed according to the clinical criteria issued by WHO with or without laboratory confirmation (table 2) [3-5, 8, 10, 59-71]. One of the case series was not included because patients treated by different treatment regimens were aggregated together and could not be analyzed [72]. There were 349 males and 500 females. Except for 13 (1.5%) patients who were treated conservatively, antiviral therapy and / or immunomodulating therapy were given in all other patients. Of 772 patients receiving specific antiviral therapy and / or immunomodulating therapy, 675 (87.4%) were treated with ribavirin containing regimens and 44 (5.7%) were treated with lopinavir/ritonavir containing regimens during the initial phase of the disease.
Immunomodulating therapy without antiviral agents was initiated in 53 of 772 (6.9%) patients. Recombinant interferon alpha, corticosteroid, and a combination of interferon alfacon-1 and corticosteroid were used in 30 (3.9%), 14 (1.8%) and 9 (1.2%) cases respectively. Of the 64 patients receiving treatment during clinical deterioration, ribavirin or oseltamivir, lopinavir/ritonavir, and convalescent plasma were given as rescue medical therapy in 32 (50%), 31 (48.4%), and 1 (1.6%) respectively. High dose pulse methylprednisolone was used during clinical deterioration such as oxygen desaturation, worsening of radiographic infiltrates in the chest, recurrent fever without evidence of nosocomial sepsis in some reports. However, the number of patients requiring pulse steroids was not mentioned in most of them [5, 8, 10, 59-62]. Furthermore, intravenous immunoglobulin, thymic peptides, and recombinant human thymus proteins were used in some patients but the clinical details were not sufficient for any meaningful analysis [61]. The overall mortality was 7.7% in these 849 SARS cases. No obvious difference was noted irrespective of whether the patients were treated by ribavirin with or without corticosteroids, corticosteroids alone, or recombinant interferon-alpha given on admission or during deterioration. However, the mortality is only 2.3% in a group of 44 patients treated by lopinavir/ritonavir, ribavirin and corticosteroids [64], and 0% for 9 patients treated with interferon alfacon-1 and corticosteroids [65]. Only 1 patient received convalescent plasma as rescue therapy [67].

Of the 152 SARS patients in our cohort, their clinical presentation, virological tests results, and treatment regimens have been previously reported [8, 10, 16]. The virus load of their nasopharyngeal, serum, stool, and urine specimens collected between day 10 and
15 after onset of symptoms are tabulated in table 3. There was no significant relationship between virus load, age, and the presence of co-morbidities. However, significant decreases in virus load were observed when lopinavir/ritonavir was added to ribavirin (table 3). It is also interesting to note that stool virus load is significantly higher in males (7.0 vs 5.5 $\log_{10}$ copies/ml, $p=0.02$), whereas that of the urine is significantly higher in females (1.6 vs 0.6 $\log_{10}$ copies/ml, $p=0.01$). Of the 111 (73%) historical controls treated with ribavirin and corticosteroids, 12 randomly selected patients had serial virus load studies performed on their nasopharyngeal specimens; their mean virus loads were 5.2, 7.3, 4.9, and 3.8 $\log_{10}$ copies/ml at day 5, 10, 15, and 20 after onset of symptoms respectively (figure 1). The decline in virus load in nasopharyngeal specimens coincided with the appearance of IgG antibody titers against SARS-CoV during the course of infection (figure 2). Since similar clinical studies of other respiratory viral pneumonias were not available in the literature except for a naturally occurring case of influenza [73], another 12 cases of experimental infection with RSV by artificial inoculation into healthy volunteers were adopted for comparison (figure 2) [74]. The virus load of influenza A and RSV peaked at day 2 and 3 respectively, whereas that of SARS-CoV occurred at day 10 after onset of symptoms (figure 1). As for the antibody response, baseline antibodies of influenza A and RSV were detectable in serum and nasal washings but antibodies against SARS-CoV were not present until day 10 after symptom onset.
Discussion

Despite exhaustive laboratory investigations, an etiological agent could be identified in only around half of the patients suffering from acute community acquired pneumonia [75]. In immunocompetent adults with community acquired pneumonia, pyogenic bacteria still constitute the majority of microbiologically documented agents in prospective studies [76, 77]. The lack of readily available rapid diagnostic tests for respiratory viral infections is one of the major reasons for the lack of reports on the natural history, pathogenesis, and treatment of viral pneumonia. Well-documented treatment regimens by randomized control trials are only available for HIV, HCV, HBV, HSV, VZV, CMV, and human influenza without pneumonia [78-93]. Moreover, in-vitro susceptibility of viruses may not correlate with clinical efficacy, as in the case of interferon-alpha used for the treatment of genital herpes [94]. No improvement in symptoms score or duration of genital lesions was found irrespective of whether systemic or topical interferon-alpha was used [95]. In the case of acute RSV bronchiolitis, the efficacy of aerosolized ribavirin was also questionable [96, 97].

Due to the lack of effective antiviral therapy for viral pneumonia, alternative strategies using immunomodulation were proposed as early as the 1970s [21]. This was not unexpected, since the cytotoxic T cell response may lead to immunopathological damage after an initial period of host damage mediated by virus induced cytolysis. The present literature review suggests that at least in the case of human influenza A and hantavirus pneumonia, steroid therapy alone may improve the outcome [20-22, 52, 53]. In the case of VZV pneumonia, the absence of mortality in cases treated with the addition of steroid
to an efficacious antiviral agent such as acyclovir seems to support such an approach [28, 29, 39-41]. Despite some decrease in mortality in patients (47.7% vs 63.4%), ribavirin is not considered as an effective antiviral for hantavirus [51-55]. However, the use of steroids during the phase of severe acute respiratory distress syndrome of hantavirus pulmonary syndrome may be associated with reduction in mortality (13.3% vs 63.4%) [52, 53]. As emphasized by a group reporting on a cluster of adenoviral pneumonia, the use of high dose steroids without an effective antiviral may actually increase mortality [47]. However the number of adenoviral pneumonia treated by steroids is too small to justify such a conclusion. Overall, the dosage and duration of steroid therapy for viral pneumonia were extremely heterogenous, future randomized clinical studies should be conducted to ascertain the dosage and duration of steroids associated with the least complication which includes secondary infection and avascular necrosis of bone.

Another difficulty in the management of viral pneumonia is the early peaking of the virus load which leaves a narrow window of opportunity for antiviral treatment [73, 74]. In both human influenza A and RSV, the virus loads peaked at around 2 to 3 days after symptom onset in natural and experimental infections of healthy adults (figure 1) [73, 74]. The early control of virus load in these two infections may be explained by the brisk antibody response, possibly due to previous antigenic exposure (figure 2) [73, 74]. A completely different picture emerges in the case of SARS. The virus load in SARS patients peaked at around day 10 with a very large area under the curve when compared with those of human influenza A and RSV (figure 1). The onset of antibody response was also delayed and started to appear at around day 10. The failure of innate immunity
and the relatively delayed onset of adaptive antibody response to control virus replication may be the explanations for the high mortality of this infection. Our previous studies showed that mortality is directly related to the virus load in nasopharyngeal specimens on admission and at day 10 [16, 98]. The mortality was also correlated with the number of RT-PCR positive specimens from different body sites including nasopharyngeal, serum, stool, or urine [98]. Therefore, an effective antiviral which could reduce the peak virus load and area under the curve is the key to the successful treatment of SARS and perhaps avian influenza A H5N1, since the general population has no immunological memory towards these two viruses.

Intravenous ribavirin was empirically used as a broad-spectrum antiviral agent at the beginning of the SARS epidemic in many countries [3-5, 8, 59-63, 66]. Ribavirin was selected as it has broad-spectrum antiviral activities possibly through the interference of cellular inosine monophosphate dehydrogenase [99]. It has been shown to be effective against mouse coronavirus in the setting of fulminant murine hepatitis [100]. Although the in-vitro antiviral activity of ribavirin is weak, it has an indirect immunomodulatory activity by decreasing the release of proinflammatory cytokines from macrophages of mice. It may also switch the immune response of mice from a T-helper-2 to a T-helper-1 response [100], which is beneficial for most intracellular infection. Subsequently in-vitro susceptibility testing suggests that antiviral effect could only be achieved at a very high concentration which is difficult to achieve clinically [101], despite the fact that ribavirin is known to be concentrated in some cell lines such as African green monkey kidney (Vero 76) and mouse 3T3 cells [102]. Moreover, the use of high dose regimens indicated
for the treatment of hemorrhagic fever was associated with significant hemolysis [12, 72]. Thus other options were diligently searched during the epidemic. Lopinavir/ritonavir was then used in addition to ribavirin because of a weak in-vitro antiviral activity on the prototype SARS-CoV [10]. The checkerboard assay demonstrated synergism between lopinavir and ribavirin at a low viral inoculum [10]. Other reports suggested that glycyrrhizin, interferon beta (Betaferon), interferon alpha n-1 (Wellferon), interferon alpha n-3 (Alferon), leucocytic interferon alpha, and baicalin may also have in-vitro activity [101, 103-105]. However, interferons were not considered by most clinicians during the epidemic because of their known proinflammatory activity, which may potentiate the inflammatory damage initiated by the viral infection, and the reported side effects of interstitial pneumonitis and bronchiolitis obliterans organizing pneumonia [106]. Subsequently pegylated recombinant interferon alpha 2b was shown to be effective as pre-exposure and perhaps very early post-exposure prophylaxis in cynomolgus macaques (Macaca fascicularis) experimentally infected with SARS-CoV [107]. Though different preparations of interferons appeared to be effective in-vitro, only recombinant interferon alpha and interferon alfacon-1 has been used in SARS patients [61, 65]. Moreover it is still early to say which interferon is likely to be effective in human trial because contradictory reports on the in-vitro susceptibility tests were reported for interferon beta 1a [101, 108] and interferon alpha 2b [101, 109].

This review has reviewed the anecdotal reports on the treatment of viral pneumonia. The findings may be biased since positive results are more likely to be reported. Steroids appeared to confer some benefit in patients with ARDS due to hantavirus, human
influenza and VZV. However, the early use of high dose steroids may be counterproductive in the absence of an effective antiviral agent. Randomized placebo controlled trials utilizing different regimens of antivirals with or without steroids should be considered for the treatment of SARS and other viral pneumonias in the future.

Acknowledgment:
We acknowledge research funding from the Vice-Chancellor SARS Research Fund, Suen Chi Sun Charitable Foundation SARS Research Fund, The University of Hong Kong. We are most grateful to Dr Rodney Lee for critical review of the manuscript.
Reference

1. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science* 2003; 302:276-8.

2. Webster RG. Wet markets--a continuing source of severe acute respiratory syndrome and influenza? *Lancet* 2004; 363:234-6.

3. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. *N Engl J Med* 2003;348:1995-2005.

4. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 2003;348:1977-85.

5. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003; 361:1319-25.

6. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. *Lancet* 1998; 351:467-71.

7. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. *N Engl J Med* 2004; 350:1179-88.

8. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and virus load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 2003; 361:1767-72.

9. World Health Organization. Summary table of SARS cases by country, 1 November 2002 – 7 August 2003. Available at: [http://www.who.int/csr/sars/country/en/country2003_08_15.pdf](http://www.who.int/csr/sars/country/en/country2003_08_15.pdf). Accessed March 25, 2004.
10. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004; 59:252-6.

11. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. *Nature* 2003; 423:4.

12. Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. *Clin Infect Dis* 2003; 37:1139-42.

13. Oba Y. The use of corticosteroids in SARS. *N Engl J Med* 2003; 348:2034-5

14. Bernard GR. Corticosteroids: the "terminator" of all untreatable serious pulmonary illness. *Am J Respir Crit Care Med* 2003; 168:1409-10.

15. Chan KH, Poon LL, Cheng VC, et al. Detection of SARS coronavirus in patients with suspected SARS. *Emerg Infect Dis* 2004; 10:294-9.

16. Cheng VC, Hung IF, Tang BS, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. *Clin Infect Dis* 2004; 38:467-75.

17. Taylor GJ, Brenner W, Summer WR. Severe viral pneumonia in young adults. *Chest* 1976; 69:722-8

18. Winterbauer RH, Ludwig WR, Hammar SP. Clinical course, management, and long-term sequelae of respiratory failure due to influenza viral pneumonia. *Johns Hopkins Med J* 1977; 141:148-55.

19. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. *Chest* 2001; 119:1717-23.
20. Kawayama T, Fujiki R, Rikimaru T, Oizumi K. Clinical study of severe influenza virus pneumonia that caused acute respiratory failure. *Kurume Med J* 2001; 48:273-9.

21. Ferstenfeld JE, Schlueter DP, Rytel MW, Molloy RP. Recognition and treatment of adult respiratory distress syndrome secondary to viral interstitial pneumonia. *Am J Med* 1975; 58:709-18.

22. Greaves IA, Colebatch HJ, Torda TA. A possible role for corticosteroids in the treatment of influenzal pneumonia. *Aust N Z J Med* 1981; 11:271-6.

23. Doi M, Takao S, Kaneko K, et al. Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction. *Intern Med* 2001; 40:61-7.

24. Chan PK. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. *Clin Infect Dis* 2002;34 Suppl 2:S58-64.

25. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet* 2004; 363:617-9.

26. Hockberger RS, Rothstein RJ. Varicella pneumonia in adults: a spectrum of disease. *Ann Emerg Med* 1986; 15:931-4.

27. Davidson RN, Lynn W, Savage P, Wansbrough-Jones MH. Chickenpox pneumonia: experience with antiviral treatment. *Thorax* 1988; 43:627-30.

28. Nilsson A, Ortqvist A. Severe varicella pneumonia in adults in Stockholm County 1980-1989. *Scand J Infect Dis* 1996; 28:121-3.

29. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. *Chest* 1998; 114:426-31.
30. Laufenburg HF. Varicella pneumonia: a case report and review. *Am Fam Physician* 1994; 50:793-6.

31. Oh HM, Chew SK. Varicella pneumonia in adults--clinical spectrum. *Ann Acad Med* Singapore 1996;25:816-9.

32. DeVaul KA, Garner CE. Varicella-zoster virus pneumonia in the adult patient. *J Emerg Nurs* 1997;23:102-4.

33. Potgieter PD, Hammond JM. Intensive care management of varicella pneumonia. *Respir Med* 1997;91:207-12.

34. Schlossberg D, Littman M. Varicella pneumonia. *Arch Intern Med* 1988;148:1630-2.

35. El-Daher N, Magnussen R, Betts RF. Varicella pneumonitis: clinical presentation and experience with acyclovir treatment in immunocompetent adults. *Int J Infect Dis* 1998;2:147-51.

36. Chou DW, Lee CH, Chen CW, Chang HY, Hsiue TR. Varicella pneumonia complicated by acute respiratory distress syndrome in an adult. *J Formos Med Assoc* 1999;98:778-82.

37. Nee PA, Edrich PJ. Chickenpox pneumonia: case report and literature review. *J Accid Emerg Med* 1999;16:147-50.

38. Hepburn NC, Carley RH. Adult respiratory distress syndrome secondary to varicella infection in a young adult. *J R Army Med Corps* 1989;135:81-3.

39. Lau LG. Adult varicella pneumonia that responded to combined acyclovir and steroid therapy. *Med J Malaysia* 1999;54:270-2.

40. Keane J, Gochuico B, Kasznica JM, Kornfeld H. Usual interstitial pneumonitis responsive to corticosteroids following varicella pneumonia. *Chest* 1998;113:249-51.
41. Ahmed R, Ahmed QA, Adhami NA, Memish ZA. Varicella pneumonia: another 'steroid responsive' pneumonia? *J Chemother* 2002;14:220-2.

42. Shirai T, Sano K, Matsuyama S, et al. Varicella pneumonia in a healthy adult presenting with severe respiratory failure. *Intern Med* 1996;35:315-8.

43. Tokat O, Kelebek N, Turker G, Kahveci SF, Ozcan B. Intravenous immunoglobulin in adult varicella pneumonia complicated by acute respiratory distress syndrome. *J Int Med Res* 2001;29:252-5.

44. Dudding BA, Wagner SC, Zeller JA, Gmelich JT, French GR, Top FH Jr. Fatal pneumonia associated with adenovirus type 7 in three military trainees. *N Engl J Med* 1972;286:1289-92.

45. Pearson RD, Hall WJ, Menegus MA, Douglas RG Jr. Diffuse pneumonitis due to adenovirus type 21 in a civilian. *Chest* 1980;78:107-9.

46. Retalis P, Strange C, Harley R. The spectrum of adult adenovirus pneumonia. *Chest* 1996;109:1656-7.

47. Klinger JR, Sanchez MP, Curtin LA, Durkin M, Matyas B. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. *Am J Respir Crit Care Med* 1998;157:645-9.

48. No authors listed. Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000. *MMWR Morb Mortal Wkly Rep* 2001;50:553-5.

49. Levin S, Dietrich J, Guillory J. Fatal nonbacterial pneumonia associated with Adenovirus type 4. Occurrence in an adult. *JAMA* 1967;201:975-7.

50. Zarraga AL, Kerns FT, Kitchen LW. Adenovirus pneumonia with severe sequelae in an immunocompetent adult. *Clin Infect Dis* 1992;15:712-3.
51. Levy H, Simpson SQ. Hantavirus pulmonary syndrome. *Am J Respir Crit Care Med* 1994;149:1710-3.

52. Castillo C, Naranjo J, Sepulveda A, Ossa G, Levy H. Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. *Chest* 2001;120:548-54.

53. Riquelme R, Riquelme M, Torres A, et al. Hantavirus pulmonary syndrome, southern Chile. *Emerg Infect Dis* 2003;9:1438-43.

54. Chapman LE, Ellis BA, Koster FT, et al. Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. *Clin Infect Dis* 2002;34:293-304.

55. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. *Antivir Ther* 1999;4:211-9.

56. Aylward RB, Burdge DR. Ribavirin therapy of adult respiratory syncytial virus pneumonitis. *Arch Intern Med* 1991;151:2303-4.

57. Rupp ME, Schwartz ML, Bechard DE. Measles pneumonia. Treatment of a near-fatal case with corticosteroids and vitamin A. *Chest* 1993;103:1625-6.

58. Haller A, von Segesser L, Baumann PC, Krause M. Severe respiratory insufficiency complicating Epstein-Barr virus infection: case report and review. *Clin Infect Dis* 1995;21:206-9.

59. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. *Lancet* 2003;361:1615-7.
60. Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. *Ann Intern Med* 2003;139:715-23.

61. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol* 2003;52:715-20.

62. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 2003;348:1986-94.

63. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. *Am J Respir Crit Care Med* 2003;168:1449-56.

64. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. *Hong Kong Med J* 2003;9:399-406.

65. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* 2003;290:3222-8.

66. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. *Emerg Infect Dis* 2003;9:713-7.

67. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med J* 2003;9:199-201.
68. No authors listed. Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:297-302.

69. No authors listed. Update: Severe acute respiratory syndrome--United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:332, 334-6.

70. No authors listed. Update: Severe acute respiratory syndrome--United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:357-60.

71. No authors listed. Update: severe acute respiratory syndrome--United States, June 11, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:550.

72. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA* 2003;289:2801-9.

73. Dolin R. Influenza: current concepts. *Am Fam Physician* 1976;14:72-7.

74. Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. *J Clin Microbiol* 2003;41:4160-5.

75. File TM. Community-acquired pneumonia. *Lancet* 2003;362:1991-2001.

76. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. *Am J Med* 1999;106:385-90.

77. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. *Chest* 1998;114:1588-93.
78. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med* 2003;349:2293-303.

79. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med* 2003;349:2304-15.

80. Jaeckel E, Comber M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 2001;345:1452-7.

81. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-82.

82. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958-65.

83. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998;339:61-8.

84. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999;341:1256-63.

85. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis* 2002;34:958-62.

86. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350:11-20.
87. Balfour HH Jr, Rotbart HA, Feldman S, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. *J Pediatr* 1992;120:627-33.

88. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. *Ann Intern Med* 1992;117:358-63.

89. Salmon-Ceron D, Fillet AM, Aboulker JP, et al. Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. *Clin Infect Dis* 1999;28:901-5.

90. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. *N Engl J Med* 2002;346:1119-26.

91. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. *Lancet* 2000;355:1845-50.

92. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. *JAMA* 2000;283:1016-24.

93. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. *Pediatr Infect Dis J* 2000;19:410-7.
94. Eron LJ, Toy C, Salsitz B, Scheer RR, Wood DL, Nadler PI. Therapy of genital herpes with topically applied interferon. *Antimicrob Agents Chemother* 1987;31:1137-9.

95. Levin MJ, Judson FN, Eron L, et al. Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences. *Antimicrob Agents Chemother* 1989;33:649-52.

96. Moler FW, Steinhart CM, Ohmit SE, Stidham GL. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. *J Pediatr* 1996;128:422-8.

97. Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 1999;160:829-34.

98. Hung IF, Cheng VC, Wu AK, et al. Relationships between virus loads in different clinical specimens and manifestations of SARS. (Manuscript submitted)

99. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new trick for an old drug? *CMAJ* 2003;168:1289-92.

100. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. *J Immunol* 1998;160:3487-93.

101. Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs. *Emerg Infect Dis* 2004;10:581-6.
102. Smee DF, Bray M, Huggins JW. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. *Antivir Chem Chemother* 2001;12:327-35.

103. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *Lancet* 2003;361:2045-6.

104. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. *Lancet* 2003;362:293-4.

105. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of ten clinical isolates of SARS coronavirus to selected antiviral compounds. *J Clin Virol* 2004 (in press).

106. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. *Am J Gastroenterol* 2002;97:2432-40.

107. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat Med* 2004;10:290-3.

108. Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. *Emerg Infect Dis* 2004;10:317-9.

109. Stroher U, DiCaro A, Li Y, et al. Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon- alpha. *J Infect Dis* 2004;189:1164-7.
Table 1. Summary of literature reported cases in the medical management of viral pneumonia other than SARS in immunocompetent host

| Antiviral therapies and / or immunomodulating agents with respect to different viral pathogens; sex & age (if mentioned) | Number of cases | Mechanical ventilation (%) | Mortality (%) | Reference |
|---|---|---|---|---|
| **Human influenza A pneumonia** – 8 M / 8 F; median age 65 years (23-80 years) | 38 | 24 (63.2) | 12 (31.6%) | 17-23 |
| Conservative treatment | 19 | 12 (63.2%) | 8 (42.1%) | 17-20 |
| Antiviral alone: Rimantadine (1), oseltamivir (5), combination of oseltamivir & rimantadine (5) | 11 | 8 (72.7%) | 3 (27.3%) | 20-23 |
| Corticosteroid alone: MP 500 mg ivi q6h (1); hydrocortisone 250 mg ivi q4h and tailing from day 6 to day 26 after admission (1) | 8 | 4 (50%) | 1 (12.5%) | 20-22 |
| **Avian influenza A H5N1 pneumonia** - 6 M / 6 F; median age of 24.5 years (16-60 years) | 12 | 6 (50%) | 8 (66.7%) | 6,7,24,25 |
| Conservative treatment | 2 | 0 (0%) | 1 (50%) | 24 |
| Antiviral alone: Amantadine (4), oseltamivir (3) | 7 | 3 (42.9%) | 5 (71.4%) | 6,24,25 |
| Antiviral & immunomodulators: Amantadine for 3 days & steroid in 1; oseltamivir for 5 days & MP 1-2 mg/kg ivi q6h for 3 and 4 days in 2 patients respectively | 3 | 3 (100%) | 2 (66.7%) | 6,7 |
| **VZV pneumonia** - 61 M / 28 F; median age of 31 years (22-88 years) | 120 | 37 (30.8%) | 11 (9.2%) | 26-43 |
| Conservative treatment | 33 | 2 (6.1%) | 4 (12.1%) | 26-29 |
| Antiviral alone: Intravenous acyclovir (66), vidarabine (2) | 68 | 26 (38.2%) | 7 (10.3%) | 27-38 |
| Antiviral & immunomodulators: Intravenous acyclovir & corticosteroid (17), intravenous acyclovir & IVIG (2) (hydrocortisone 200 mg ivi q6h for 2 days in 6; hydrocortisone 100 mg ivi q6h and tailing over 1 month in 1; P 60 mg po qd and tailing over 32 weeks in 1; MP 60 mg ivi q6h for 2 days in 1 patient) | 19 | 9 (47.4%) | 0 (0%) | 28,29,39-43 |
| **Adenoviral pneumonia** - 7 M / 3 F; median age of 22 years (18-48 years) | 29 | 12 (41.4%) | 6 (20.7%) | 21,44-50 |
| Conservative treatment | 25 | 10 (34.5%) | 4 (16%) | 44-48 |
| Corticosteroid alone | 4 | 2 (50%) | 2 (50%) | 21,44,49,50 |
| **Hantavirus pulmonary syndrome** - 30 M / 11 F; median age of 33 years (15-63 years) | 100 | 25/56 (44.6%) | 49 (49%) | 51-55 |
| Conservative treatment | 41 | 18/26 (69.2%) | 26 (63.4%) | 51-53 |
| Antiviral alone: intravenous ribavirin | 44 | NM | 21 (47.7%) | 51,54,55* |
| Corticosteroid alone | 15 | 7 (46.7%) | 2 (13.3%) | 52,53 |
| **RSV pneumonia** - F / 64; aerosolized ribavirin 6 gm 22 hours daily for 5 days | 1 | 1 (100%) | 0 | 56 |
| **Measles pneumonia** - F / 29; MP 1 gm ivi daily for 2 days and tailing dose thereafter; vitamin A 200,000U orally for 2 days | 1 | 1 (100%) | 0 | 57 |
| **EBV pneumonia** - M / 30; P 100 mg po daily for 11 days then tailing gradually | 1 | 1 (100%) | 0 | 58 |

Note. EBV, Epstein-Barr virus; MP, methylprednisolone; NM, not mention; P, prednisolone; ivi, intravenously; IVIG, intravenous immunoglobulin; RSV, respiratory syncytial virus; VZV, varicella-zoster virus; * patients described in reference 55 were also reported in reference 54.
### Table 2. Summary of literature reported cases in the medical management of SARS in adult

| Antiviral therapies and / or immunomodulating agents, in addition to empirical broad spectrum antibiotics therapy | Number of cases | Sex (M:F) | Non-invasive ventilation (%) | Mechanical ventilation (%) | Pulse MP for clinical deterioration (%) | Mortality (%) | Reference |
|---|---|---|---|---|---|---|---|
| Conservative supportive treatment | 13 | 7:6 | 0 | 4 (30.8%) | 0 | 2 (15.4%) | 3,5,59,60,68-71 |
| **Initial medical management (n=772)** | | | | | | | |
| Ribavirin with or without oseltamivir | 47 | 19:28 | 10 (21.3%) | 6 (12.8%) | 0 | 3 (6.4%) | 3 |
| Ribavirin & corticosteroid | 611 | 263:348 | 4 (0.7%) | 104 (17%) | 54 / 95 (56.8%) | 47 (7.7%) | 4,5,8,59-63 |
| Ribavirin & high dose pulse MP | 17 | 7:10 | 0 | 1 (5.9%) | 4 (23.5%) | 1 (5.9%) | 63 |
| Lopinavir/ritonavir, ribavirin & corticosteroid | 44 | 12:32 | 0 | | | | |
| Corticosteroid | 14 | 3:11 | 0 | 3 (21.4%) | 2 (14.3%) | 1 (7.1%) | 65,68 |
| Interferon alfacon-1 & corticosteroid | 9 | 3:6 | 0 | 1 (11.1%) | 5 (55.6%) | 0 | 65 |
| Recombinant interferon alpha | 30 | 11:19 | 8 (26.7%) | 2 (6.7%) | 0 | 2 (6.7%) | 61 |
| **Rescue medical treatment (n=64)** | | | | | | | |
| Ribavirin or oseltamivir | 20 | 5:15 | 0 | 6 (30%) | 0 | 3 (15%) | 66 |
| Ribavirin & corticosteroid | 12 | 6:6 | 0 | 12 (100%) | NM | 1 (8.3%) | 5 |
| Convalescent plasma | 1 | F | 0 | 0 | 1 (100%) | 0 | 67 |
| Lopinavir/ritonavir | 31 | 13:18 | 0 | 3 (9.7%) | 31 (100%) | 4 (12.9%) | 64 |

Note. MP, methylprednisolone; SARS, severe acute respiratory syndrome; SARS-CoV, SARS associated coronavirus. * 12 patients reported in reference 10 were included in reference 64.
Table 3. Correlation of demographic data, treatment intervention, and quantitative RT-PCR of clinical specimens between day 10 and 15 in 152 patients with SARS

| Demographic data & treatment intervention | Nasopharyngeal specimens (n = 152) | Serum (n = 53) | Stool (n = 94) | Urine (n = 111) |
|------------------------------------------|------------------------------------|----------------|---------------|---------------|
|                                          | Mean (SD) virus load (log₁₀ copies / ml) | Mean (SD) virus load (log₁₀ copies / ml) | Mean (SD) virus load (log₁₀ copies / ml) | Mean (SD) virus load (log₁₀ copies / ml) |
| Age                                      |                                     |                |               |               |
| Age equal or more than 60 years (n=20)   | 2.5 (3.0)                           | 1.2 (1.3)      | 6.7 (3.4)     | 1.4 (2.3)     |
| Age less than 60 years (n=132)           | 2.3 (3.1)                           | 1.1 (1.5)      | 6.0 (3.0)     | 1.3 (2.1)     |
| P value                                  | 0.83                                | 0.96           | 0.46          | 0.84          |
| Sex                                       |                                     |                |               |               |
| Male (n=58)                              | 2.9 (3.3)                           | 1.4 (1.4)      | 7.0 (2.6)     | 0.6 (1.6)     |
| Female (n=94)                            | 2.0 (2.9)                           | 1.0 (1.4)      | 5.5 (3.2)     | 1.6 (2.3)     |
| P value                                  | 0.11                                | 0.44           | 0.02          | 0.01          |
| Co-morbidity                             |                                     |                |               |               |
| Presence of co-morbidity (n=28)          | 2.9 (3.3)                           | 1.1 (1.7)      | 5.9 (3.4)     | 1.2 (2.1)     |
| Absence of co-morbidity (n=124)          | 2.2 (3.0)                           | 1.1 (1.4)      | 6.1 (3.0)     | 1.3 (2.1)     |
| P value                                  | 0.31                                | 0.89           | 0.78          | 0.79          |
| Lopinavir/ritonavir therapy in addition to ribavirin | | | | |
| Presence of lopinavir/ritonavir therapy (n=41) | 1.3 (2.6)                           | 0.4 (0.9)      | 4.3 (3.3)     | 0.5 (1.4)     |
| Absence of lopinavir/ritonavir therapy (n=111) | 2.8 (3.1)                           | 1.4 (1.5)      | 6.9 (2.6)     | 1.7 (2.3)     |
| P value                                  | <0.01                               | 0.04           | <0.01         | <0.01         |
Sequential quantitative measurements of viral shedding from upper respiratory tract during infections with influenza virus, respiratory syncytial virus (RSV), and SARS coronavirus (SARS-CoV). Influenza virus quantitation was performed on throat washings from a naturally occurring case of influenza in a 28-year-old male. Influenza A / Victoria H3N2 virus was isolated using cell cultures [73]. RSV quantitation was done on nasal washings from 12 subjects inoculated nasally with $10^{4.7}$ TCID$_{50}$ (50 median tissue culture infectious dose) RSV A2 challenge pool of virus, developed by the National Institute of Allergy and Infectious Diseases. RSV virus load was measured by quantitative RT-PCR using primers based on the nucleotide sequences from the F gene of RSV group A and B viruses [74]. SARS-CoV quantitation was performed on nasopharyngeal specimens from infected patients. SARS-CoV virus load of 12 patients are measured by quantitative RT-PCR of Pol gene from nasopharyngeal specimens.

Changing titers of serum antibody of influenza A, nasal IgA of RSV, and IgG of SARS-CoV after onset of symptoms. Serum antibody titer (HAI) of influenza A was determined using serial sera from a patient who was naturally infected with influenza A virus (same patient as shown in Figure 1). Mean RSV nasal IgA titers were obtained from nasal washings of 12 subjects who were inoculated with RSV (same group of patients as shown in Figure 1). Mean IgG titers of SARS-CoV were obtained using sera from 12 patients who were infected with SARS-CoV (same group of patients as shown in Figure 1).
Figure 1.

Sequential virus load in patients infected with Influenza A, RSV, and SARS-CoV

Time after onset of symptoms, days
Log10 virus load (RSV & SARS-CoV)
TCID50 titer (Influenza A)

- RSV
- SARS-CoV
- Influenza A
Figure 2.

Sequential antibody level in patients infected with Influenza A, RSV, and SARS-CoV.